Therapies
RGCC THERAPIES
There is no one-size-fits-all approach to treating chronic disease. Every patient and their disease are different and they will respond to treatment in their own unique way. Our team of multi-disciplinary scientists combines groundbreaking research with best-in-class technology to develop targeted therapies to improve patient outcomes.
The field of advanced therapy medicinal products (ATMPs) has enormous potential to fulfill previously unmet medical needs. Our scientists are working to translate this potential into reality with a range of ATMPs to effectively treat a range of chronic diseases, including cancer. SOT THERAPY
SUPPORTIVE OLIGONUCLEOTIDE THERAPY (SOT- Apoptosis Inducer)
SOT is a personalized therapy for cancer, viruses and pathogens including Lyme Disease. The SOT has the ability to bind to a specific gene of interest that controls the cancer cell or pathogen by disrupting the critical process that promotes its survival or growth. During this therapy, we analyze a patient’s blood and create a complementary oligonucleotide sequence designed to interrupt the cells’ survival or growth. RGCC SOTs are available to RGCC Network doctors. Please contact us to discuss your requirements.
PRE-REQUISITE TEST: (Patient must have an R.G.C.C. ONCOCOUNT/R.G.C.C Oncotrace within the last 6 months.)
REQUIREMENT: 15-25 ml Blood
THERAPY PREPARATION: 10-15 Working days (from the day the sample reaches the lab)
POST-TREATMENT FOLLOW-UP: Oncocount or Oncotrail are recommended after 3 months of the administration to evaluate CTCs’ number or their immunophenotype for the 1st year. Blood samples 20-25ML should be sent to the lab.
DENDRITIC CELL THERAPY
DENTRITIC CELLS
DCs are exceptionally powerful initiators of immunity, with the ability to activate an immune response more potently than any other cell in the immune repertoire. Dendritic cells are a type of antigen presenting cells (APC) that play an important role in the adaptive immune system. They have the capacity to induce a primary immune response in the inactive or resting naïve T lymphocytes. To do this DCs capture antigens from invading bodies, which they process and present on their cell surface along with the necessary co-stimulation molecules. They also contribute to the function of B cells and help maintain their immune memory. Cancer malignancies are often treated by administering a DC vaccine during the premalignant stages, prior to development of immune suppression.
RGCCs laboratories use patients’ isolated monocytes as a source for the in vitro production of DCs. DCs are then pulsed with synthesized peptides that are dependent on the antigens expressed on the cancer cells from each patient. This way we are able to obtain mature DCs specific for a patient’s tumor antigens, leading to a more personalized treatment.
PRE-REQUISITE TEST: (Patient must have an R.G.C.C. ONCOCOUNT and IMMUNE-FRAME within the last 6 months.)
REQUIREMENT: 90 – 120 ML Blood
THERAPY PREPARATION:21-25 days (from the day the sample reaches lab)
POST-TREATMENT FOLLOW-UP: Follow up blood samples should be sent to our lab at specific time points (Day 63 after 1st administration). They will be used to assess activation of immune system and DCs biological efficiency.
Optional: Between 2nd and 3rd dose Immune-Frame. Blood sample 20-25ML should be sent to lab.
ATA - Vaccine Prep from Tumour Cell Antigens
VACCINE PREP FROM FRAGMENTED TUMOR CELL ANTIGENS (ATA)
Autologous vaccines are created from a patient’s cancer cells, which are isolated from a blood sample. The cancer cells are cultured (effectively grown) in the laboratory, where they are combined with an immuno-stimulant designed to stimulate the body’s immune system into action.
The disrupted cancer cells, now called tumour cell antigens, are re-administered into the patient through a vaccine. They provide the immune system with the blueprint to eliminate any remaining cancer cells in the body. The vaccine enables the body’s immune system to target and destroy cancer cells while leaving healthy tissue untouched.
PRE-REQUISITE TEST: Before ATA therapy order, Immune-Frame and Oncotrace tests should also be ordered
REQUIREMENT: 25 ml Blood
THERAPY PREPARATION: 15 Working Days (from the day the sample reaches lab)
POST-TREATMENT FOLLOW-UP: The interval time for Immune-Frame is 21 (3 weeks) days after the administration of the last (6th) dose.
VAXO-Q-Re
VAXO-Q-RE
Vaxo-Q-Re is a new advanced therapy consisting of five types of immune cells; macrophages, NK cells, dendritic cells, cytotoxic T lymphocytes and antibody producing plasma cells. Tested on breast cancer cells but effective at treating all forms of the disease, the adoptive T cell-based therapy encourages the body’s immune system to target cancer cells. Vaxo-Q-Re has been in development by RGCC scientists for more than five years and is now categorized as a Cell Therapy Medicinal Product (CTMP) by the European Medicines Agency (EMA).
PRE-REQUISITE TEST: (Patient must have an R.G.C.C. IMMUNE FRAME and ONCOTRACE within the last 6 months.)
REQUIREMENT: 120-150ML Blood
THERAPY PREPARATION: 21-25 Days (from the day the sample reaches lab)
POST-TREATMENT FOLLOW-UP: Follow up blood samples should be sent to our lab at specific time points (Day 120 and Day 210). They will be used to assess VAXO-Q-RE efficiency for each individual and generate a report.